Using functional ex vivo assays and mass cytometry analysis, defects in the regulatory B cell repertoire was found to predispose NSCLC patients to the development of immune related toxicity following anti-PD-1(L1) blockade (120). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.